Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Rating Lowered by StockNews.com

Vanda Pharmaceuticals (NASDAQ:VNDA) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Monday.

Separately, TheStreet downgraded shares of Vanda Pharmaceuticals from a “c-” rating to a “d” rating in a research note on Thursday, February 8th.

Vanda Pharmaceuticals Stock Down 3.5 %

NASDAQ VNDA opened at $4.63 on Monday. The stock has a market cap of $266.40 million, a P/E ratio of 92.60 and a beta of 0.76. Vanda Pharmaceuticals has a twelve month low of $3.30 and a twelve month high of $7.00. The company’s 50-day simple moving average is $4.26 and its 200 day simple moving average is $4.07.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Wednesday, February 7th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.05. Vanda Pharmaceuticals had a net margin of 1.30% and a return on equity of 0.46%. The company had revenue of $45.27 million for the quarter, compared to analyst estimates of $37.00 million. Research analysts anticipate that Vanda Pharmaceuticals will post -0.06 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in VNDA. CWM LLC lifted its stake in Vanda Pharmaceuticals by 61.1% in the third quarter. CWM LLC now owns 7,205 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 2,732 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Vanda Pharmaceuticals during the 3rd quarter worth about $85,000. Exchange Traded Concepts LLC acquired a new stake in shares of Vanda Pharmaceuticals during the 3rd quarter worth about $1,009,000. Allspring Global Investments Holdings LLC lifted its stake in shares of Vanda Pharmaceuticals by 56.4% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 313,619 shares of the biopharmaceutical company’s stock worth $1,355,000 after buying an additional 113,139 shares during the last quarter. Finally, CTC Alternative Strategies Ltd. acquired a new stake in shares of Vanda Pharmaceuticals during the 3rd quarter worth about $79,000. Institutional investors own 88.14% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.